Thrivent Financial for Lutherans’s iTeos Therapeutics ITOS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,556	Closed	-$563K	–	2502
2025 Q2	$563K	Buy	56,556 +7,411	+15%	+$59.7K	﹤0.01%	2090
2025 Q1	$293K	Buy	+49,145	New	+$361K	﹤0.01%	2240
2023 Q4	–	Sell	-24,223	Closed	-$265K	–	2517
2023 Q3	$265K	Buy	24,223 +616	+3%	+$7.88K	﹤0.01%	2330
2023 Q2	$313K	Sell	23,607 -719	-3%	-$10.3K	﹤0.01%	2322
2023 Q1	$331K	Sell	24,326 -853	-3%	-$15.3K	﹤0.01%	2269
2022 Q4	$492K	Sell	25,179 -195	-0.8%	-$3.81K	﹤0.01%	2125
2022 Q3	$483K	Buy	25,374 +5,471	+27%	+$126K	﹤0.01%	2086
2022 Q2	$410K	Buy	19,903 +3,535	+22%	+$83.9K	﹤0.01%	2164
2022 Q1	$527K	Buy	+16,368	New	+$595K	﹤0.01%	2166

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Thrivent Financial for Lutherans's ITOS Position: Q3 2025 in Review

Thrivent Financial for Lutherans sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 56,556 shares — an estimated $563K sold.

Thrivent Financial for Lutherans first reported a position in ITOS in Q1 2022 and held it in 9 quarters. The position peaked at $563K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Thrivent Financial for Lutherans reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Thrivent Financial for Lutherans sold 56,556 iTeos Therapeutics shares in Q3 2025, an estimated $563K.
Thrivent Financial for Lutherans first reported a position in iTeos Therapeutics in Q1 2022 and held it in 9 quarters.
Thrivent Financial for Lutherans's iTeos Therapeutics position peaked at $563K in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2025, filed 4 Nov 2025.